TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01101880

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study: NCT01091974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: armodafinil
Description: Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: armodafinil
Description: Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Placebo for 47 days
Study: NCT00272545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normalization of Eating (NOE)
Description: The NOE is a 6-week program based on principles of CBT. Participants will receive individual therapy, as well as take part in group and family therapy sessions. In addition, participants will be supervised while eating meals.
Study: NCT01091974

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo for 47 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)
Study: NCT04511169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital self-help
Description: The digital self-help program is targeting every-day ADHD symptoms in adults with a diagnosed ADHD
Study: NCT00272545

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: Treatment as usual will include standard care for a person with an eating disorder.
Study: NCT03203590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Navelbine + Carboplatin
Description: The patient will be given Navelbine 60 mg/m2, p.o. day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v. day 1 of every cycle.After 2 cycle we will evaluate their clinical response.Then operable patients will have surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: The patient will be given Gefitinib 250mg,p.o.,q.d. for 8 weeks.After 8 weeks we evaluate their clinical response.Then operable patients will have surgery.
Study: NCT00788697

Intervention type: DRUG
Group type: OTHER
Intervention: SonoVue-enhanced ultrasound
Description: Contrast-enhanced ultrasound (CE-US) examination of the target lesion. Drug: SonoVue® Dose of 2.4 mL bolus injection administered intravenously. Maximum of 2 injections (4.8 mL)

Intervention type: OTHER
Group type: OTHER
Intervention: Unenhanced ultrasound
Description: -Unenhanced: Gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion. Drug: None
Study: NCT03700632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patch therapy
Description: The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week
Study: NCT00680953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate sodium hydrate
Description: Oral tablet once a week for 24 months
Study: NCT01601470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 400mg QD was administered alone for 4 days and in combination with sildenafil for 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil 50 mg single dose was administered alone for 1 days and in combination with LCZ696 400mg QD for 1 day
Study: NCT05049447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pascoflair
Description: 1 x 2 tablets (single-dose)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 x 2 tablets (single-dose)
Study: NCT02322411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isometric Progressive Resistance Oropharyngeal Therapy
Description: Isometric Progressive Resistance Oropharyngeal Therapy is an approach to oropharyngeal strengthening. This particular use of I-PRO therapy will be facilitated by the Swallow Strong device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Compensatory approaches

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compensatory approaches
Study: NCT02463136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Clinical questionnaires and behavioural computer-based paradigms, such as the Overlap task (Cohen Kadosh et al., 2014)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging w neurofeedback
Description: The general framework of the scanning part of this experiment consists of a localiser task (lasting approximately 8 minutes), 4 neurofeedback runs (each lasting approximately 5 minutes) and an anatomical scan (approximately 10 minutes).~Immediately prior and following the scanning session, participants will also be asked to completed several), as well as an attentional control task with emotional stimuli, such as a behavioural version of the Overlap task (Cohen Kadosh et al., 2014).
Study: NCT00555906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Escalating doses of bortezomib will be administered intravenously on Days 8, 11, 15 and 18 of a 28-day cycle (Schedule A) or of a 21-day cycle (Schedule B). The planned doses to be evaluated are 0.7, 1 and 1.3 mg/m2 in combination with PD 0332991 and dexamethasone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg, orally on Days 8, 11, 15 and 18 of a 28 day cycle (Schedule A) or of a 21-day cycle (Schedule B) in combination with PD 0332991 and bortezomib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991
Description: Escalating doses of PD 0332991 will be administered orally on Days 1-21 of a 28-day cycle for Schedule A and on Days 1-12 of a 21-day cycle for Schedule B. The planned doses to be evaluated are 50, 75, 100 mg and 125 mg once daily in combination with bortezomib and dexamethasone.
Study: NCT01856322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac
Description: one tablet 150mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet twice daily

Intervention type: OTHER
Group type: OTHER
Intervention: Validate assays and shipping methods
Study: NCT03251027

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IM-SRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life
Description: Ancillary studies
Study: NCT04111705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: 100 mg once daily
Study: NCT01478464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: The hamstring muscle will be massaged with a massage roller for ten minutes.
Study: NCT04437173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset Distraction
Description: Patient wears a virtual reality headset during interventional pain procedure
Study: NCT03992209

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Usual operating room practice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocolized care
Description: Hand washing per protocol
Study: NCT01830816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules
Study: NCT04508725

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Doppler Ultrasound
Description: Power doppler measurements will be made

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Doppler Ultrasound
Description: Power doppler measurements will be made

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIEMENS S3000 and Verasonics Vantage 256
Description: Vantage 256 used for power doppler ultrasound, manufactured by Verasonics

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIEMENS S3000 and Verasonics Vantage 256
Description: Vantage 256 used for power doppler ultrasound, manufactured by Verasonics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vascular Endothelial Growth Factor Receptor 2 tyrosine kinase inhibitor plus immune checkpoint inhibitor
Description: Participants will receive less than 4 weeks of TKI treatment during the first 12 weeks. Plus immune checkpoint inhibitor (arm 1) or non-immune checkpoint inhibitor (arm 2)
Study: NCT02576886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma Camera
Description: All images acquired with the General Electric Discovery 530c

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone Imaging
Study: NCT02319213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraocular pressure measurement with 9 mmHg insufflation
Description: Comparison of intraocular pressure levels at different abdominal pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraocular pressure measurement with 12 mmHg insufflation
Description: Comparison of intraocular pressure levels at different abdominal pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraocular pressure measurement with 15 mmHg insufflation
Description: Comparison of intraocular pressure levels at different abdominal pressure
Study: NCT01761513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808
Description: Group1~1. adminitration of YH4808 dose1, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, qd for 2weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808
Description: Group1~1. adminitration of YH4808 dose1, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, qd for 2weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YH4808
Description: Group1~1. adminitration of YH4808 dose1, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, qd for 2weeks
Study: NCT02128594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serosorting Intervention
Description: Single session, behavioral intervention
Study: NCT03623425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET
Description: a 68GA-PSMA-11 PET exam before the a 18F-FCH PET exam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET
Description: a 68GA-PSMA-11 PET exam before the a 18F-FCH PET exam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FCH PET
Description: a 18F-FCH PET exam before the 68Ga-PSMA-11 PET exam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FCH PET
Description: a 18F-FCH PET exam before the 68Ga-PSMA-11 PET exam
Study: NCT00407173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCV-796
Description: HCV-796 1000mg single dose
Study: NCT04655053

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal intention
Description: Researcher instructs participants to adopt and learn the goal intention requesting them to write it three times and verbally repeat once.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation intention to initiate the behavior
Description: Researcher instructs participants to adopt and learn the goal intention and the plan requesting them to write it three times and verbally repeat once.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation intention to manage the goal preference (avoiding behavior or not)
Description: Researcher instructs participants to adopt and learn the goal intention and the plan requesting them to write it three times and verbally repeat once.
Study: NCT01357980

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 750 U intra detrusor injection on Day 1 (single dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 750 U intra detrusor injection on Day 1 (single dose)
Study: NCT02117011

Intervention type: OTHER
Group type: OTHER
Intervention: Physical Activity
Description: Those participants randomized to the exercise group will be required to exercise 5 days/week for 8 weeks coinciding with the radiation treatment sessions. The exercise intervention will consist of aerobic training. Participants will be required to meet and maintain a goal of 75 min/week of aerobic exercise by using portable cycle ergometers; that is; 15 min/day for 5 days/week. The cycle ergometer consists of two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. The tension on the pedals can be adjusted to provide desired tension. Patients can also move the equipment so they can use it conveniently while sitting anywhere and with any chair.
Study: NCT02315222

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regenium

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Full Mouth Disinfection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full Mouth Disinfection
Study: NCT02100293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulfate 30 mg/kg
Description: Patients in each group received the magnesium sulfate 30 mg/kg for 2 min in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
Study: NCT02486497

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hENT1
Description: hENT1 is a membrane transporter for gemcitabine. According to the hENT1 staining, patients will be treated with gemcitabine or 5-FU.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hENT1
Description: hENT1 is a membrane transporter for gemcitabine. According to the hENT1 staining, patients will be treated with gemcitabine or 5-FU.
Study: NCT01866293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib (XL184)
Study: NCT04468854

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Luteolin
Description: Luteolin extracted from Chrysanthemum Ramat 98% HPLC by Scyherb® food grade certified according to Safe Quality Foods (SQF) - Level 3 Comprehensive Food Safety and Quality Management System Certification by the Safe Quality Food Institute (SQFI).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: mannitol formulated for oral administration (capsules)
Study: NCT01251237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL0706
Description: Patients receive 1 litre of NRL0706 solution followed by 0.5 litre of clear liquid during the afternoon/evening prior to colonoscopy. Patients receive 1 litre of 0706 solution followed by 0.5 litre of clear liquid during the morning of colonoscopy.
Study: NCT01525810

Intervention type: DRUG
Intervention: Peginterferon Lambda-1a (BMS-914143)
Description: Observational study - No Intervention \[subjects were previously treated with Peginterferon Lambda-1a (BMS-914143)\]
Study: NCT03445208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Crossover administration to abdomen then upper arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Crossover administration to abdomen then upper arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Crossover administration to abdomen then upper arm
Study: NCT01970046

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Metformin
Description: * Run in period ：placebo and metformin 500 mg t.i.d for 6 weeks~* Phase A : Placebo and metformin 500 mg t.i.d for 24 weeks~* Phase B : SP2086 50 mg b.i.d and metformin 500 mg t.i.d for 28 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086 50 mg b.i.d/Metformin
Description: * Run-in period: placebo and Metformin 500 mg t.i.d for 6weeks~* Phase A:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 28 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086 50 mg q.d./Metformin
Description: * Run-in period: placebo and Metformin 500 mg t.i.d for 6 weeks~* Phase A:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 28 weeks
Study: NCT02834260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone implant OZURDEX
Study: NCT00518284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticle Paclitaxel
Description: Nanoparticle albumin-bound paclitaxel, 45 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticle Paclitaxel
Description: Nanoparticle albumin-bound paclitaxel, 45 mg/m\^2.
Study: NCT02100293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: Patients in each group received 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: Patients in each group received 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
Study: NCT01357980

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intra detrusor injection on Day 1 (single dose)
Study: NCT03665259

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pure oxygen group
Description: pre-oxygenation with 100% oxygen during induction of anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lower oxygen group
Description: Pre-oxygenation with 60% oxygen during induction of anesthesia
Study: NCT02399644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: ACT is a type of Cognitive behavioral Therapy (CBT) that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
Study: NCT00518284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticle Paclitaxel
Description: Nanoparticle albumin-bound paclitaxel, 45 mg/m\^2.
Study: NCT02571777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVM149 150/50/160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVM149 150/50/80

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QMF149 150/320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QMF149 150/160
Study: NCT03078023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: swallowed sponge device
Description: Swallowed sponge: Subjects having a clinical upper endoscopy will be asked to swallow the sponge 2 hours prior to EGD
Study: NCT02288611

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Date fruit - Ajwa variety
Description: Twenty-two healthy human individuals were randomly assigned to consume 7 date fruits (approx. 50g). Each arm was 21 days in duration, separated by a 14 days washout period.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin/Dextrose
Description: Twenty-two healthy human individuals were randomly assigned to consume Maltodextrin/dextrose , 40.2g. Each arm was 21 days in duration, separated by a 14 days washout period.
Study: NCT02781350

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: HFHC meal
Description: 900 Cal high fat high carbohydrate fast food meal (HFHC). meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HFHC MEAL plus Fiber
Description: 900 Cal high fat high carbohydrate fast food meal containing egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).with FiberOne Original cereal 14 grams (half cup) each before and after the HFHC meal
Study: NCT01661166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: 4 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study: NCT01705964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM epinephrine 1:1000
Description: IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
Study: NCT04791787

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard weight maintaining diet
Description: Diet containing diet approximately 25-35% protein, 45-55% carbohydrate, 20- 30% fat

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight maintaining isocaloric ketogenic diet
Description: Isocaloric ketogenic diet containing approximately 15-25% protein, 5-10% carbohydrate,70- 80% fat

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight maintaining isocaloric ketogenic diet
Description: Isocaloric ketogenic diet containing approximately 15-25% protein, 5-10% carbohydrate,70- 80% fat

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beta-hydroxy butyrate
Description: A supplement of ketone ester of beta-hydroxy butyrate
Study: NCT00633308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NxStage System One (NxStage Medical, Lawrence, MA)
Description: Each patient will be studied on 4 separate occasions. The study sessions are longer than routine daily hemodialysis therapy using the System One.